Trial Profile
Phase I study of Abt-530 in healthy adults.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 May 2017
Price :
$35
*
At a glance
- Drugs Pibrentasvir (Primary) ; Ritonavir
- Indications Hepatitis C
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors AbbVie
- 21 Apr 2016 New trial record
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics